ChileTuberculosis profile
Population  2017 18 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.43 (0.41–0.44) 2.4 (2.3–2.4)
Mortality (HIV+TB only) 0.079 (0.04–0.13) 0.44 (0.22–0.73)
Incidence  (includes HIV+TB) 3.2 (2.7–3.6) 17 (15–20)
Incidence (HIV+TB only) 0.51 (0.31–0.77) 2.8 (1.7–4.3)
Incidence (MDR/RR-TB)** 0.085 (0.056–0.12) 0.47 (0.31–0.66)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.15 (0.15–0.16) 1 (0.91–1.1) 1.1 (1–1.3)
Males 0.17 (0.16–0.17) 1.8 (1.6–2) 2 (1.8–2.2)
Total 0.32 (0.3–0.33) 2.8 (2.4–3.2) 3.2 (2.7–3.6)
TB case notifications, 2017  
Total cases notified 2 806
Total new and relapse 2 740
          - % tested with rapid diagnostics at time of diagnosis 3%
          - % with known HIV status 83%
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.16 (0.13–0.19)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 261 11%
          - on antiretroviral therapy    
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  53
(36–70)
Estimated % of TB cases with MDR/RR-TB 2% (1.3–2.8) 5.9% (2.2–12)  
% notified tested for rifampicin resistance 62% 67% 1 747
MDR/RR-TB cases tested for resistance to second-line drugs   37
Laboratory-confirmed cases MDR/RR-TB: 37, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 34, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 79% 2 548
Previously treated cases, excluding relapse, registered in 2016    
HIV-positive TB cases registered in 2016 54% 240
MDR/RR-TB cases started on second-line treatment in 2015 37% 19
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions) 3
Funding source: 8% domestic,  international, 92% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-11-15 Data: www.who.int/tb/data